Related Experiment Video

Updated: Jul 16, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

A worldwide perspective of atypical pathogens in community-acquired pneumonia

Forest W Arnold1, James T Summersgill, Andrew S Lajoie

  • 1Division of Infectious Diseases, University of Louisville, Louisville, KY 40292, USA. f.arnold@louisville.edu

American Journal of Respiratory and Critical Care Medicine
|March 3, 2007
PubMed
Abstract

Insights

Empiric treatment for community-acquired pneumonia (CAP) should include atypical pathogen coverage. This approach improves clinical outcomes, reduces hospital stays, and lowers mortality rates in hospitalized patients with CAP.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Public Health

Background:

  • International guidelines debate the necessity of atypical pathogen coverage in community-acquired pneumonia (CAP) treatment.
  • Monotherapy with beta-lactam antimicrobials is a common initial approach in many global regions.

Purpose of the Study:

  • To correlate the global incidence of atypical pathogens in CAP with regional treatment patterns.
  • To compare clinical outcomes for CAP patients receiving atypical pathogen coverage versus those who did not.

Main Methods:

  • Secondary analysis of two international databases.
  • Categorization of world regions into North America, Europe, Latin America, and Asia/Africa.
  • Comparison of time to clinical stability, hospital length of stay, and mortality rates.

Main Results:

  • Atypical pathogens were present in 20-28% of CAP cases across regions.
  • Atypical coverage varied significantly by region (10-91%).
  • Patients receiving atypical coverage showed improved clinical stability, shorter hospital stays, and reduced mortality.

Conclusions:

  • Atypical pathogens are globally prevalent in CAP.
  • Antimicrobial regimens including atypical coverage are associated with better patient outcomes.
  • Empiric CAP therapy should incorporate atypical pathogen coverage for all hospitalized patients.

More Related Videos

Tools for the Real-Time Assessment of a Pseudomonas aeruginosa Infection Model07:39

Tools for the Real-Time Assessment of a Pseudomonas aeruginosa Infection Model

Published on: April 6, 2021

Related Concept Videos

Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Microbiota of the Respiratory Tract01:29

Microbiota of the Respiratory Tract

The human respiratory tract, comprising the upper and lower segments, serves as a critical interface with the external environment. The upper respiratory tract (URT)—including the nostrils, sinuses, pharynx, and oropharynx—is heavily colonized by microbes, while the lower respiratory tract (LRT), composed of the larynx, trachea, bronchi, and lungs, was long thought to be sterile. However, recent molecular studies have revealed that the lungs are not devoid of microbes but act more like...